BOSTON--(BUSINESS WIRE)--Symbiotix Biotherapies, Inc., a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome, announced that Sheila Mikhail, J.D., M.B.A., has joined the company’s Board of Directors as Executive Chairman.
Sheila Mikhail brings over twenty years of biopharmaceutical expertise to Symbiotix. She is Co-Founder and Chief Executive Officer of Asklepios Biopharmaceuticals, a company she started in 2002. She most recently served as Co-Founder and Chief Executive Officer of Bamboo Therapeutics, which was acquired by Pfizer in August 2016 in a deal valued at $860 million. Prior to that, she was part of the management team at Chatham Therapeutics, which was acquired by Baxter. Earlier, she was Co-Founder and Chief Executive Officer of NanoCor Therapeutics, Inc., which completed a strategic partnership and investment with Medtronic. Trained as a lawyer, Ms. Mikhail practiced law for over 15 years, including a law firm that she founded, Life Sciences Law, which serviced clients such as Bayer, Gilead, GSK, Sanofi, and Aventis. She also practiced with Ropes and Gray in Boston. She received a J.D., with honors, from Northwestern University, a finance M.B.A., with honors, from the University of Chicago, and a B.S., with highest honors, from the University of Illinois at Urbana-Champaign.
“We are delighted to have Sheila Mikhail joining us as Executive Chairman. In light of the notable progress Symbiotix has made in advancing our programs, the addition of such a distinguished biopharma veteran positions Symbiotix to rapidly drive forward our strategy to take ZPS therapeutics into the clinic,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “Sheila brings a unique combination of expertise in law, business and biopharma that will enable Symbiotix to best leverage its intellectual property.”
About Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. At Symbiotix, we are developing a novel class of ZPS therapeutics based on molecules derived from the human microbiome. ZPS therapeutics, which have been described in over 100 scientific publications, represent the most widely tested molecules from the human microbiome and are the basis of first-in-class oral agents for the treatment of serious immune-mediated diseases such as multiple sclerosis (MS) and inflammatory bowel disease (IBD). For more information, please visit www.symbiotix-bio.com.
